Literature DB >> 12804445

Antidepressants for cocaine dependence.

M S Lima1, A A Reisser, B G Soares, M Farrell.   

Abstract

BACKGROUND: Cocaine dependence is a common and serious condition, which has become a substantial public health problem. The past decade has witnessed a sustained search for an effective pharmacotherapeutic agent for the treatment of cocaine dependence. While administration of cocaine acutely increases intercellular dopamine, serotonin, and norepinephrine levels by blocking their presynaptic reuptake, chronic cocaine abuse leads to down-regulation of monoamine systems. Post-cocaine use depression and cocaine craving may be linked to this down-regulation. Antidepressant pharmacotherapy, by augmenting monoamine levels, may alleviate cocaine abstinence symptomatology, as well as relieving dysphoria and associated craving by general antidepressant action.
OBJECTIVES: To conduct a systematic review of all RCTs on the use of antidepressants for treating cocaine dependence. SEARCH STRATEGY: We searched the Cochrane Controlled Trials Register (Cochrane Library, issue 4, 2000), MEDLINE (from 1966 - 2000), EMBASE (from 1980 - 2000), LILACS (from 1982 - 2000), PsycLIT (from 1974 - 2000), Biological Abstracts (1982 to 2000). Other searches:reference searching; personal communication; conference abstracts; unpublished trials from pharmaceutical industry; book chapters on treatment of cocaine dependence. SELECTION CRITERIA: The inclusion criteria for all randomised controlled trials were that they should focus on the use of antidepressants on the treatment of cocaine dependence. Trials including patients with additional diagnosis such as opiate dependence were also eligible. DATA COLLECTION AND ANALYSIS: The reviewers extracted the data independently and Relative Risks, weighted mean difference and number needed to treat were estimated. The reviewers assumed that people who died or dropped out had no improvement and tested the sensitivity of the final results to this assumption. MAIN
RESULTS: 18 studies were included in the review, with 1177 people randomised. Positive urine sample for cocaine metabolites was the main efficacy outcome, with no significant results obtained regardless of the type of antidepressant. Compared to other drugs, desipramine performed better but showing just a non significant trend with heterogeneity present as revealed by the chi-square test (8.6, df=3; p=0.04). One single trial showed imipramine performed better than placebo in terms of clinical response according to patient's self-report. A similar rate of patients remaining in treatment was found for both patients taking desipramine or placebo. Results from one single trial suggest fluoxetine patients on SSRIs are less likely to dropout. Similar results were obtained for trials where patients had additional diagnosis of opioid dependence and/or were in methadone maintenance treatment. REVIEWER'S
CONCLUSIONS: There is no current evidence supporting the clinical use of antidepressants in the treatment of cocaine dependence. Given the high rate of dropouts in this population, clinicians may consider adding psychotherapeutic supportive measures aiming to keep patients in treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804445     DOI: 10.1002/14651858.CD002950

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  19 in total

1.  A perfect platform: combining contingency management with medications for drug abuse.

Authors:  Kathleen M Carroll; Bruce J Rounsaville
Journal:  Am J Drug Alcohol Abuse       Date:  2007       Impact factor: 3.829

Review 2.  Novel approaches to the treatment of cocaine addiction.

Authors:  Mehmet Sofuoglu; Thomas R Kosten
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy.

Authors:  Daniel Ciccarone
Journal:  Prim Care       Date:  2011-01-11       Impact factor: 2.907

Review 4.  Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.

Authors:  Leonard L Howell; S Stevens Negus
Journal:  Adv Pharmacol       Date:  2014

5.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

Review 6.  Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside.

Authors:  Steven M Graves; Roueen Rafeyan; Jeffrey Watts; T Celeste Napier
Journal:  Pharmacol Ther       Date:  2012-08-29       Impact factor: 12.310

7.  Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study.

Authors:  D A Nielsen; M J Harding; S C Hamon; W Huang; T R Kosten
Journal:  Genes Brain Behav       Date:  2012-09-27       Impact factor: 3.449

Review 8.  Psychostimulant addiction treatment.

Authors:  Karran A Phillips; David H Epstein; Kenzie L Preston
Journal:  Neuropharmacology       Date:  2014-04-12       Impact factor: 5.250

Review 9.  Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage.

Authors:  Yasmin L Hurd; Michelle Yoon; Alex F Manini; Stephanie Hernandez; Ruben Olmedo; Maria Ostman; Didier Jutras-Aswad
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 10.  Animal models and treatments for addiction and depression co-morbidity.

Authors:  Neil E Paterson; Athina Markou
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.